SecurityBMY / Bristol-Myers Squibb Co.
InstitutionBridgewater Associates, LP
ManagerRay Dalio, Bob Prince
Shares273,634
Value $ 15,143,000
Related 110122AT5 / Bristol-meyers Squibb Co. 2.0% 08/01/22
110122AU2 / Bristol-meyers Squibb Co. 3.25% 08/01/42
110122AS7 / Bristol-meyers Squibb Co. .875% 08/01/17
110122AL2 / Bristol-myers Squibb 5.25% Senior Notes 08/15/13
110122AR9 / Bristol-myers Squibb 5.45% Notes 5/1/18
110122AQ1 / Bristol-myers Squibb 6.125% Notes 5/1/38
BMYMP / Bristol-Myers Squibb Co.
110122AP3 / Bristol-myers Squibb Co 5.875% Bonds 11/15/36
110122AB4 / Bristol-myers Squibb Co 6.800% Debentures 11/15/26
110122AC2 / Bristol-myers Squibb Co 6.875% Debs 08/1/2097
110122AA6 / Bristol-myers Squibb Co 7.150% Debentures 06/15/23
110122AN8 / Bristol-Myers Squibb Co. Bond
ADI0M9WV6 / Bristol-Myers Squibb Co. Bond

Bridgewater Associates, LP ownership in BMY / Bristol-Myers Squibb Co.

August 13, 2018 - Bridgewater Associates, LP has filed a 13F-HR form disclosing ownership of 273,634 shares of Bristol-Myers Squibb Co. (NYSE:BMY) with total holdings valued at $15,143,000 USD as of June 30, 2018. Bridgewater Associates, LP had filed a previous 13F-HR on November 13, 2017 disclosing 0 shares of Bristol-Myers Squibb Co. at a value of $0 USD.

Other investors with positions similar to Bridgewater Associates, LP include Barrett Asset Management, LLC, Brown Advisory Inc, Mairs & Power INC, Norinchukin Bank, The, Creative Planning, and Franklin Street Advisors Inc /nc.

Bristol Myers Squibb Company has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Bridgewater Associates, LP's top industries are "Printing, Publishing, And Allied Industries" (sic 27), "Rubber And Miscellaneous Plastics Products" (sic 30), and "Stone, Clay, Glass, And Concrete Products" (sic 32).

Bridgewater Associates, LP ownership in BMY / Bristol-Myers Squibb Co.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR BRISTOL MYERS SQUIBB COM 110122108 273,634 15,143 15,143 0
2017-09-30 13F-HR BRISTOL MYERS SQUIBB COM 110122108 0 -100.00 0 -100.00 -7,303 0
2017-06-30 13F-HR BRISTOL MYERS SQUIBB COM 110122108 55.05 131,064 35.58 7,303 38.92 1,893 153 2.90
2017-03-31 13F-HR BRISTOL MYERS SQUIBB COM 110122108 96,670 5,257 5,257 0
2016-12-31 13F-HR BRISTOL MYERS SQUIBB COM 110122108 0 -100.00 0 -100.00 -21,060 0
2016-09-30 13F-HR BRISTOL MYERS SQUIBB COM 110122108 63.74 390,577 109.48 21,060 53.57 13,010 -5,664 -41.30
2016-06-30 13F-HR BRISTOL MYERS SQUIBB COM 110122108 68.72 186,454 114.70 13,714 147.19 6,845 1,321 23.81
2016-03-31 13F-HR BRISTOL MYERS SQUIBB COM 110122108 66.33 86,845 22.58 5,548 13.85 1,061 -386 -7.93
2015-12-31 13F-HR BRISTOL MYERS SQUIBB COM 110122108 63.99 70,845 262.79 4,873 321.54 3,284 433 37.47
2015-09-30 13F-HR BRISTOL MYERS SQUIBB COM 110122108 19,528 0.00 1,156 1,156 0
2014-12-31 13F-HR BRISTOL MYERS SQUIBB COM 110122108 0 -100.00 0 -100.00 -523 0
2014-09-30 13F-HR BRISTOL MYERS SQUIBB COM 110122108 51.54 10,228 130.98 523 127.39 299 -6 -2.57
2014-03-31 13F-HR BRISTOL MYERS SQUIBB COM 110122108 4,428 230

Related SEC Filings

BMY / Bristol-Myers Squibb Co. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
bristolmyerssquibbco.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Bristol-Myers Squibb Co     Title of Class of Securities:  Common Stock     CUSIP Number:  110122108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

BMY / Bristol-Myers Squibb Co. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
bristolmyerssquibbco.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Bristol-Myers Squibb Co     Title of Class of Securities:  Common Stock     CUSIP Number:  110122108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

BMY / Bristol-Myers Squibb Co. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Bristol-Myers Squibb Company (Name of Issuer) Common Stock (Title of Class of Securities) 110122108 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The r

BMY / Bristol-Myers Squibb Co. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Bristol-Myers Squibb Company (Name of Issuer) Common Stock (Title of Class of Securities) 110122108 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The r

BMY / Bristol-Myers Squibb Co. / BlackRock Inc. - 3G/A (Passive Investment)

2018-02-08 sec.gov
us1101221083_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) BRISTOL-MYERS SQUIBB COMPANY -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 110122108 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -----------------------------------------

Related News Stories

OncoMed: Undervalued With A Promising Pipeline

2h seekingalpha
Navicixizumab (Navi) is blowing away the standard of care in later line ovarian cancer [data at ESMO]. (2-0)

A Company In Decline? The Case For/Against Affimed After Bad News

2018-10-14 seekingalpha
Affimed has built a technology platform focused on immune cell-engaging antibodies for therapeutic effect in oncology. (1-0)

Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

2018-10-12 zacks
This week was a relatively quiet one for the pharma sector ahead of earnings. In key developments, AbbVie (ABBV - Free Report) signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J (JNJ - Free Report) gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb (BMY - Free Report) signed a new oncology collaboration with Compugen to study a combination of their cancer drugs for advanced solid tumors. (16-0)

AVEO Pharmaceuticals Enters A Critical Juncture Amid Stock Market Uncertainty. Will Its TKI-That-Could Prevail?

2018-10-12 seekingalpha
Expansions of reimbursement and hope for approval in the US are important catalysts for the company in the near term. (3-0)

How Compugen Is Weathering Thursday’s Storm

2018-10-11 247wallst
Compugen Ltd. (NASDAQ: CGEN) shares pushed higher on Thursday after it was announced that Bristol-Myers Squibb Co. (NYSE: BMY) will make a $12 million equity investment as part of its collaboration on a cancer trial. (6-1)



CUSIP: 110122108